Document is current
Any future updates will be listed below
-
Authors
Niznik, Taylor
Boozary, Laili K.
Chen, Meng
Cohn, Amy M.
Ulahannan, Susanna V.
Henson, Christina E.
Alexander, Adam C.
Moore, Kathleen N.
Holman, Laura L.
Queimado, Lurdes
Kendzor, Darla E.
-
Funding
Funding for this research was provided by:
Oklahoma Tobacco Settlement Endowment Trust (R22-03)
National Institute on Minority Health and Health Disparities (1K01MD015295-01A1)
National Cancer Institute Cancer Center Support (P30CA225520)
- License Information
-
More Information
Article History
Received: 1 August 2024
Accepted: 31 October 2024
First Online: 16 November 2024
Declarations
:
: Kendzor and Businelle are inventors of the Insight Mobile Health Platform (not used or evaluated in the current study) and receive royalties for the external use of the platform outside of the University of Oklahoma Health Sciences Center. Kendzor is a member of the Scientific Advisory Board of Qnovia. Inc., which is a drug development company focused on inhaled therapies including prescription inhaled nicotine replacement therapy for smoking cessation (no medications provided or evaluated in the current study). Kendzor previously received medication (varenicline) at no cost from Pfizer to support a now completed pilot study (no medications provided or evaluated in the current study). The authors declare no competing interests.
